Street Calls of the Week
ALDERLEY PARK - TheraCryf plc (AIM:TCF), a clinical stage drug development company focused on brain disorders, acknowledged World Mental Health Day today while announcing its conference schedule for the final quarter of 2025.
World Mental Health Day, observed annually on October 10, aims to raise awareness of mental health issues globally. According to the World Health Organization, more than 1 billion people worldwide live with a mental health condition, with anxiety and depression being the most common.
TheraCryf is developing an orexin-1 antagonist targeting binge eating disorder and other substance use disorders. The company’s lead Ox-1 program is being positioned as a potential treatment for anxiety and addictive behaviors.
"As we mark World Mental Health Day, we are very much aware of the impact mental health conditions have on quality of life for sufferers and their families," said Dr. Huw Jones, CEO of TheraCryf, in a press release statement. "We are on track with our work to enable our orexin-1 blocker to be used in clinical trials in under a year from now."
The company also announced its leadership team will attend several industry and investor conferences during Q4, including BioSeed North in Manchester on October 21, BioEurope in Vienna from November 3-5, and London Life Sciences Week & Jefferies Global Healthcare Conference in London from November 17-21.
TheraCryf’s Chief Operating Officer, Dr. Helen Kuhlman, recently published an article on orexin-based treatments for addictive behaviors in the European Biopharmaceutical Review.
The company’s broader pipeline includes programs targeting addiction, anxiety, fatigue, narcolepsy, glioblastoma, and neurodevelopmental disorders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.